History

Home > About CCSB > History
Chunghwa Chemical Synthesis & Biotech Co. Ltd.,(CCSB) is the first company which got FDA approval to produce synthesis and biotechology API products in the South-East Asia.
2009 Got approval from German GMP in late June; Business volume of Mycophenolate Mofetil over NTD 500 millions; List on OTC successfully in October.
2008 Mycophenolate Mofetil be stably exported to US market, and the business volume of which over NTD 200 millions.
2007 Trandolapril、Olopatadineand Perindolpril be toll manufactured; Contract manufacturing items increased, and the business volume of which targeted 25% of total sales.
2006 Carisoprodol be launched; Tacrolimus be stably exported to US market; Business volume of Pravastatin over NTD 200 million.
2005 Rapamycin be stably exported to US market ; Got approval from FDA again for both Synthesis & Biotechnology cGMP plants in December.
2004 Rapamycin be commercialized; Tacrolimus be launched; Dr. I-Der Hunag retired, and Dr. Steve H. Chang be appointed President.
2003 Cooperated with Europe Pharmacist to mutually develop Trandolapril & Perindopril; Mycophenolate Mofetil be commercialized; Methocarbamol took the largest share in US market; Company name be changed as Chunghwa Chemical Synthesis & Biotech Co., Ltd.; Reached profit for the first year after company transformed; Export sales targeted nearly 90% of the annual business turnover.
2002 Got FDA approval for the Synthesis cGMP Palnt; Got approval from BFDA (Bureau of Food and Drug Analysis, Department of Health).
2001 Dexbromopheniramine maleate and Methocarbamol be launched.
2000 Pravastatin be commercialized; Rapamycin、Mycophenolate Mofetil and Alprazolam be launched .
 
1999 Construction of 4 new cGMP plants completed; US Sales Office formed; Famotidine be launched. 
1998 Mr. Derek Wang be appointed Chairman; Construction of 2 new Biotech cGMP plant started; Fluoxetine be launched.
1997 Dr. I-Der Huang be appointed President; Partnership with China Development Industrial Bank (CDIB); Construction of 2 new Synthesis cGMP plants started; Fluconazole be launched.
1995 Calcium Polycarbofil, Melatonin & Glibenclamide be launched
1994 Construction of waste treatment plant completed; Glipizide & Nifedipine be launched.
1992 Mr. Xie-Xiong Tsai be appointed President; Cefatrizine be launched.
1991 Norfloxacin & Flumequine be launched.

1990

 Construction of Research Center started; Research Operations for Synthesis, Biotech and Formulation started; Invest San-Ta Pharmaceutical company for production GGE & SSG.
 
1986 6-APA production plant completed.
1984 Cefadroxil be launched; Got approval from FDA and became the first authorised company to produce API in the South-East Asia.
1983 Rifamycin be launched.
1982 Cefalexin be launched.
1981 Erythromycin Estolate be launched.
1980 Amoxycillin be launched.
 
1975 2nd Production plant completed for production Penicillin derivatives product; Ampicilin & Cloxacillin be launched.
 
1969 Thiamine Propyl Disulfide be launched.
1967 Acetaminophen, Bucetin be launched.
1966 1st Production plant completed.
1965 45,800㎡ production site purchased.
1964 Mr. Ming-Ning Wang found CCSB, Chloramphenicol and loropheniramine Maleatebe launched.